Long-Term Study of Bivamelagon in Hypothalamic Obesity
Tests bivamelagon, a long-term extension, in people with hypothalamic obesity who joined a prior study.
Plain-language title generated from the registry record
Registry title: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Key facts
- Where
- Birmingham, Cambridge, and London, United KingdomSee the 3 sites
- Phase
- Phase 2
Where in United Kingdom
- Birmingham Women's and Children's NHS Foundation TrustBirmingham, United KingdomNo longer taking part
- University of CambridgeCambridge, United KingdomNo longer taking part
- Great Ormond Street Hospital for ChildrenLondon, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rhythm Pharmaceuticals, Inc.
- Trial code
- NCT07156578
- Record updated
- 10 February 2026
- Original description
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.Read full original descriptionShow less
A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Inclusion: Completed LG-MCCL005 and participant demonstrated adequate safety and tolerability in that study as determined by the Investigator; Agree to use a highly effective form of contraception and follow contraception requirements throughout the study and for 90 days after.
Exclusion: Willing to remain off of: CYP3A4 inhibitors, strong CYP3A4 inducers, and P-glycoprotein inhibitors or substrates for the duration of the study; In the opinion of the Investigator, participant is not suitable to participate in the study; Other protocol defined Inclusion/Exclusion criteria may apply.